Clinical trials: Refractory Chronic Cough
Refractory/Unexplained Chronic Cough
ATP Level and Cough Sensitivity to ATP in Subjects With Refractory/Unexplained Chronic Cough
This is a cross-sectional study to investigate ATP level in induced sputum and cough sensitivity to ATP in subjects with refractory/unexplained chronic cough.
- Trial name
- NCT05265871
- Where
- China
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Kefang Lai
Refractory Chronic Cough
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough
- Trial name
- NCT03282591
- Testing
- 5 mg Serlopitant Tablets
- Where
- 39 sites in United States, United Kingdom
- Volunteers
- 185 people
- Sponsor
- Vyne Therapeutics Inc.
Refractory Chronic Cough
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
This study is designed to evaluate the efficacy of three dose regimens of gefapixant ([MK-7264] 7.5 mg, 20 mg, and 50 mg) relative to placebo in reducing awake objective cough frequency.
- Trial name
- NCT02612610
- Testing
- Gefapixant
- Volunteers
- 253 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Refractory Cough
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough
- Trial name
- RELIEF (NCT03979638)
- Testing
- BLU-5937
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Bellus Health Inc. - a GSK company
Chronic Cough
Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)
This estimation study (no hypotheses) will evaluate the safety, tolerability, and efficacy of gefapixant (MK-7264) in Japanese adult participants with unexplained or refractory chronic cough.
- Trial name
- NCT03482713
- Testing
- Gefapixant 45 mg
- Where
- 16 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Cough
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Chronic Cough
- Trial name
- NCT05392192
- Testing
- ADX-629
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Cough
Pilot of Zinc Acetate to Improve Chronic Cough
The Pilot of Zinc Acetate to Improve Chronic Cough (ZICO) is a study of 36 patients with chronic refractory cough that will be used to (1) assess if zinc acetate (150 mg/day) will improve patient reported measures of cough, (2)…
- Trial name
- ZICO (NCT03135522)
- Testing
- Zinc Acetate 50 Mg Oral Capsule
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Johns Hopkins University
Chronic Cough
Evaluation of S-600918 in Adults With Refractory Chronic Cough
The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared…
- Trial name
- NCT04110054
- Testing
- S-600918
- Where
- 136 sites in United States, Czechia and 4 more
- Volunteers
- 406 people
- Sponsor
- Shionogi
Cough
Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients
Persistent cough is a distressing symptom for people with respiratory disorders. Patients also often experience an ongoing urge-to-cough that prompts coughing, and which fails to resolve the sensation.
- Trial name
- NCT03722849
- Testing
- Adenosine Triphosphate, Capsaicin, Functional Brain Imaging
- Where
- Australia
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Stuart Mazzone
Cough
Cough Desensitization Therapy for Cough Hypersensitivity Syndrome
The purpose of this study is to investigate a modified behavioral treatment for chronic cough due to cough hypersensitivity syndrome (CHS).
- Trial name
- NCT04256733
- Testing
- Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer, Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Montana
Chronic Cough
A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)
The primary objective of this study is to evaluate the safety of two doses of gefapixant (MK-7264) in Japanese adult participants with refractory or unexplained chronic cough.
- Trial name
- NCT03696108
- Testing
- Gefapixant
- Where
- 61 sites in Japan
- Volunteers
- 175 people
- Sponsor
- Merck Sharp & Dohme LLC
Refractory Chronic Cough
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
The main purpose of this study is to evaluate the effect of NAL ER on 24-hour cough frequency and to assess safety and tolerability of NAL-ER for treatment of refractory chronic cough.
- Trial name
- RIVER (NCT05962151)
- Testing
- NAL ER
- Where
- 14 sites in Canada, United Kingdom
- Volunteers
- 66 people
- Sponsor
- Trevi Therapeutics
Refractory Chronic Cough
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
The primary objective of this double-blind crossover study is to assess the effect of single doses of 50 mg and 300 mg gefapixant (AF-219/MK-7264) on cough reflex sensitivity to capsaicin in both healthy participants and…
- Trial name
- NCT02397460
- Testing
- Gefapixant
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Refractory Chronic Cough
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)
The primary objective of this study was to assess the effect of a single dose of gefapixant 100 mg on cough reflex sensitivity to various challenge agents (capsaicin, citric acid, adenosine triphosphate [ATP], and distilled…
- Trial name
- NCT02476890
- Testing
- Gefapixant 100 mg
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Refractory and/or Unexplained Chronic Cough
Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
Researchers in this study want to find the optimal therapeutic dose of drug BAY1817080 for patients with long-standing cough with or without clear causes (refractory and/or unexplained chronic cough, RUCC).
- Trial name
- PAGANINI (NCT04562155)
- Testing
- BAY1817080
- Where
- 99 sites in United States, Argentina and 17 more
- Volunteers
- 310 people
- Sponsor
- Bayer
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with…
- Conditions
- Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05660850
- Testing
- GDC-6599, Mannitol
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Refractory Chronic Cough
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.
- Trial name
- NCT02612623
- Testing
- Gefapixant
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Refractory Chronic Cough
A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
A randomized, double-blind, placebo-controlled, crossover, dose escalation study to assess the efficacy and tolerability of gefapixant (AF-219; MK-7264) in participants with refractory chronic cough.
- Trial name
- NCT02349425
- Testing
- Gefapixant
- Volunteers
- 59 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Refractory Cough
A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough
The purpose of this study is to determine the effectiveness of three doses of orvepitant, taken once a day, in the treatment of chronic refractory cough.
- Trial name
- NCT02993822
- Testing
- Orvepitant Maleate
- Where
- 66 sites in United States, Canada and 1 more
- Volunteers
- 315 people
- Sponsor
- Nerre Therapeutics Ltd.
Cough, Chronic Disease
Internet-Behavioral Cough Suppression Therapy
The goal of this randomized, placebo-controlled, clinical trial is to develop and test the efficacy of an Internet-based behavioral intervention for refractory chronic cough.
- Trial name
- NCT05770401
- Testing
- Internet-Behavioral Cough Suppression Therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Montana